Drug Profile
Research programme: HIV-1 integrase inhibitors - Inhibitex
Latest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator University of Georgia
- Developer Inhibitex
- Class Pyridones
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 15 Sep 2007 Preclinical trials in HIV-1 infections in USA (IV)
- 15 Sep 2007 Preclinical trials in HIV-1 infections in USA (PO)